According to a multicenter, double-blind, sham-controlled trial published in the American Journal of Psychiatry (Carmi et al., 2019), deep TMS for OCD produced a 38.1% response rate in the active treatment group versus just 11.1% in the sham group, with improvements sustained at least four weeks after treatment ended.

For the estimated 2 to 3% of Americans living with OCD, those numbers matter. OCD is a condition where first-line treatments, primarily medication and cognitive behavioral therapy (CBT), leave a significant portion of patients without adequate relief. Standard antidepressants help roughly 40 to 60% of OCD patients, and even those who respond often continue experiencing intrusive thoughts and compulsions that interfere with daily life.

Deep TMS for OCD offers a clinically validated, non-pharmacological path forward for people who have not gotten far enough with medication or therapy alone. It is not a replacement for those approaches but a powerful complement to them, backed by the only FDA clearance for a noninvasive device in OCD treatment.

What Is Deep TMS for OCD?

Deep TMS (dTMS) is a form of transcranial magnetic stimulation that uses a specialized H-coil design to reach deeper and broader brain regions than conventional TMS. Where standard TMS coils stimulate cortical tissue roughly 0.7 to 1.0 cm beneath the scalp, the BrainsWay H7-coil used in dTMS for OCD reaches the anterior cingulate cortex (ACC) and the medial prefrontal cortex (mPFC), areas that are structurally and functionally implicated in the obsessive-compulsive cycle.

How Does It Target OCD Specifically?

OCD involves hyperactivity in the cortico-striato-thalamo-cortical (CSTC) circuit, a neural loop responsible for filtering and responding to perceived threats. In people with OCD, this circuit essentially gets stuck in a loop, generating intrusive thoughts and driving compulsive behaviors as a response. Deep TMS modulates the excitability of this circuit through repeated magnetic stimulation, helping to normalize the runaway signaling that sustains OCD symptoms.

A distinctive feature of the BrainsWay Deep TMS OCD protocol is symptom provocation before each session. Patients are briefly exposed to their specific OCD triggers just before stimulation begins. This activates the relevant neural circuits, making them more receptive to the therapeutic effect of the magnetic pulses. Research suggests this provocation step meaningfully enhances outcomes compared to unstimulated treatment.

What Does the Research Show About dTMS for OCD?

The FDA-Clearance Trial

The pivotal multicenter trial that led to FDA clearance in August 2018 enrolled 94 patients with moderate to severe OCD who had previously failed to respond adequately to medication or psychological treatment. Over six weeks of five-sessions-per-week treatment, the active dTMS group showed a 6.7-point reduction in Y-BOCS scores (the gold-standard OCD severity measure) compared to a 3.6-point reduction in the sham group. That translates to more than three times the clinical benefit over placebo.

Critically, the improvements held at the one-month follow-up assessment, confirming that the gains were not simply a short-term effect.

Real-World Data Beyond the Trial

Post-marketing data collected from 22 clinical sites and 219 patients, published in ScienceDirect, found that dTMS for OCD achieved a response rate comparable to the controlled trial in actual clinical practice, a meaningful finding because real-world outcomes frequently fall short of controlled trial results. Patients who responded showed a significant reduction in functional disability: average unproductive days per week dropped from 5.5 before treatment to 1.8 after, per a durability study published in the Brain Stimulation Journal (2021).

Deep TMS for OCD produces functional improvement, not just symptom reduction. That distinction matters to patients whose OCD has affected their work, relationships, and quality of life.

Who Is a Good Candidate for Deep TMS for OCD?

Patients Who Tend to Benefit Most

Deep TMS is FDA-cleared for adults with OCD and is particularly relevant for those who:

• Have not achieved adequate symptom control with at least one SSRI or SNRI trial
• Are in therapy but continue to experience significant obsessions or compulsions
• Want a medication-free or medication-reduced treatment component
• Can commit to the five-sessions-per-week schedule over six weeks

Patients already engaged in ERP (exposure and response prevention) therapy are especially strong candidates. The provocation protocol built into deep TMS OCD treatment is structurally similar to ERP, and the two approaches reinforce each other.

Who Should Not Pursue This Treatment

Standard TMS contraindications apply: metal implants in or near the skull, active seizure disorders, and certain neurological conditions rule out candidacy. A thorough clinical evaluation is always the first step. Not every patient with OCD will be a fit, and an honest assessment of prior treatment history helps determine whether dTMS is the right next step.

What Are the Practical Considerations?

Treatment Schedule and What to Expect

A standard dTMS for OCD course involves 29 to 30 sessions, administered five times per week over six weeks. Each session lasts approximately 20 minutes, including the symptom provocation period beforehand. Sessions require no sedation, and patients can drive themselves and return immediately to normal activities afterward.

Most patients do not experience dramatic change in the first week. Symptom improvement tends to emerge gradually, with many responders noticing meaningful shifts in weeks three to five. Some patients continue to improve in the weeks after the final session, as the neuroplastic changes consolidate.

Limitations Worth Knowing

The response rate of 38% in the pivotal trial is clinically significant, particularly given the severity and treatment resistance of the enrolled population. But it also means that not every patient responds, and managing expectations honestly is part of responsible treatment planning. Insurance coverage for dTMS for OCD is available through many major insurers but varies by plan and requires documentation of prior treatment attempts. Confirming coverage before starting is an essential step your provider can help navigate.

Key Takeaways

Deep TMS is the only FDA-cleared noninvasive device treatment for OCD, and its clinical evidence is built on the strongest study design in the field: a multicenter, double-blind, sham-controlled trial. For patients who have cycled through medications and therapy without sufficient relief, it offers a mechanistically distinct, well-characterized option with a meaningful functional impact.

If you are considering deep TMS for OCD in the Brooklyn or New York City area, contact LifeQuality TMS to schedule a consultation and find out whether you are a candidate.

Frequently Asked Questions

What is deep TMS for OCD and how is it different from standard TMS? 

Deep TMS uses a specialized H7-coil that penetrates deeper into the brain than standard TMS coils, reaching the anterior cingulate cortex and medial prefrontal cortex, regions directly involved in OCD’s neural circuitry. Standard TMS coils cannot reliably reach these structures. Deep TMS is also the only FDA-cleared noninvasive device specifically indicated for OCD.

Is BrainsWay Deep TMS for OCD FDA cleared? 

Yes. The BrainsWay Deep TMS system received FDA de novo clearance for OCD in August 2018, following a multicenter, double-blind, sham-controlled trial. It is the first and only noninvasive medical device to receive this clearance for OCD treatment.

How effective is dTMS for OCD? 

In the pivotal FDA-clearance trial, 38.1% of patients in the active treatment group achieved a clinically meaningful response, versus 11.1% in the sham group. Post-marketing data from 22 real-world clinical sites found comparable response rates in practice, and durability data shows sustained functional improvement months after treatment.

How many sessions does deep TMS for OCD require? 

The standard protocol involves 29 to 30 sessions, five days per week over six weeks. Each session lasts approximately 20 minutes. No sedation is required, and patients can return to their normal daily activities immediately after each appointment.

Can I do deep TMS for OCD while staying on my medication? 

Yes. Deep TMS for OCD is typically used as an adjunct to existing treatment, not a replacement for it. Most patients continue their prescribed medications and any ongoing therapy throughout the treatment course. Changes to your medication regimen should always be discussed with your prescribing provider.

Is deep TMS for OCD covered by insurance? 

Many major insurance plans cover dTMS for OCD when medical necessity criteria are met, typically requiring documentation of prior medication trials that did not produce adequate relief. Coverage details vary by plan, and your treatment provider can help you understand what documentation is needed and submit the appropriate prior authorization.